BRAINSTORM CELL THERAPEUTICS INC.

On July 2, 2026, the Company issued an unsecured convertible promissory note (the “July 2 Note”) in the principal amount of $115,000, receiving $96,500 in cash proceeds after an original issue discount of $15,000. Under the July 2 Note, $18,071 is payable on each of January 4, 2027, February 2, 2027, March 2, 2027, April 2, 2027, May 3, 2027, June 2, 2027 and July 2, 2027. The July 2 Note bears interest at 10% and matures on July 2, 2027.

On July 6, 2026, the Company issued an unsecured convertible promissory note (the “July 6 Note”) in the principal amount of $151,800, receiving $125,000 in cash proceeds after an original issue discount of $19,800. The July 6 Note carries a 12% one-time interest charge, matures in 12 months, and requires scheduled amortization payments beginning on December 30, 2026. The July 6 Note carries a 12% one-time interest charge, matures in 12 months, and requires scheduled amortization payments beginning on December 31, 2026.

The July 2 Note and the July 6 Note were sold in reliance upon an exemption from the registration requirement of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D promulgated thereunder.

The disclosure set forth in this Item 5 is intended to satisfy the Company’s disclosure obligations under Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant), and Item 3.02 (Unregistered Sales of Equity Securities) of Form 8-K with respect to the July 2 Note and the July 8 Note, and accordingly the Company is not filing a separate Current Report on Form 8-K with respect to these transactions. The foregoing summaries of the July 2 Note and the July 6 Note do not purport to be complete and are qualified in their entirety by reference to the full text of the forms of the July 2 Note and July 6 Note, copies of which are filed as exhibits to this Quarterly Report on Form 10-Q and are incorporated herein by reference.

During the quarter ended June 30, 2026, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Exchange Act)adopted, terminated ormodified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).